




**Life Sciences & Biotech Innovation in Asia**  
**Stanford University – Nov 15, 2007**

# A Vibrant Business Hub - Singapore










- ✓ **Springboard to Asia:**  
7,000 MNCs, Regional cultural awareness
- ✓ **English speaking workforce:** 98% literacy  
Only Asian country with English as first language
- ✓ **Open immigration policy:**  
4 mil population, of which 1 mil are non-Singaporeans
- ✓ **Pro-Business Environment**  
Lowest risk business hub  
#1 Labour Force





# A Centre for Global Companies

**7,000** MNCs, 60% of which has HQ activities  
Including many Fortune 500 companies

<p><u>Electronics &amp; Precision Engrg</u></p> 	<p><u>Biomedical Sciences</u></p> 	<p><u>Info-comm &amp; Media</u></p> 	<p><u>Chemicals</u></p> 
<p><u>Education Services</u></p> 		<p><u>Engineering Services</u></p> 	
<p><u>Retail/Restaurants</u></p> 	<p><u>Hospitality</u></p> 		<p><u>Logistics &amp; Transport</u></p> 

# Corporate Research & Development

Many MNCs choose to site R&D centres in Singapore to take advantage of our excellent infrastructure and skilled workforce



# Vision

## the **Biopolis** of Asia

An International Biomedical Sciences Cluster

Advancing **Human Health**

Through the Pursuit of Excellence in

**Research & Development, Manufacturing, and Healthcare Delivery**




Entire value chain of activities



Across industry sectors



# Building R&D Capabilities




\*Set-up as BTU in 1990. Became BTC in 1995, established as BTI in 2003

^ The Centre for Molecular Medicine (CMM) was established in 2004, and was repositioned to Institute of Medical Biology in 2007

# The Biopolis

## Centre for Biomedical Sciences R&D



### Phase 2

- 2 buildings for corporate labs
- Additional 400,000 sqft
- Construction commenced in June '05
- Officially opened on 30 October '06

### Phase 3

- Request for proposal from developers by 3Q07
- Expected to be ready by 2Q09

### Shared Facilities

- Shared R&D equipment
- Shared utilities
- Shared animal facility

### Phase 1

- 2 million sqft
- S\$500 million invested
- Public R&D centres & corporate labs



# Growing Base of Drug Discovery



- 150 RSEs
- Oncology biomarker research & genomic data analysis
- Drug Hunting Teams for cancer and metabolic diseases
- Integrated computational science research



- 60 RSEs
- Drug discovery for neuro-degenerative diseases
- Medicinal chemistry



- 40 RSEs
- In-vivo pharmacology
- Target validation



- 40-man team
- 42 beds
- Phase 1 unit



- 85 RSEs
- Drug discovery for TB, Dengue and Malaria



- 80 RSEs (projected)
- R&D in biocatalysis



Albany Molecular Research, Inc.




- 15 RSEs by 2008
- Drug development for infectious diseases



Regional Clinical Research Management



# A Coordinated Approach





[www.bio1capital.com](http://www.bio1capital.com)

**Thank You.**

